2 Days
Source:
The Washington Post
_1777370220974_847775619.png&w=48&q=75){kind=small}
Controversial sleep and pain products gain support
FDA scientists advised against approving the peptides due to insufficient clinical trial data on their safety and effectiveness.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)